Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015 (2015), Article ID 718975, 9 pages
http://dx.doi.org/10.1155/2015/718975
Research Article

IL-10 and ARG-1 Concentrations in Bone Marrow and Peripheral Blood of Metastatic Neuroblastoma Patients Do Not Associate with Clinical Outcome

1Laboratorio di Oncologia IRCCS Istituto Giannina Gaslini, 16148 Genova, Italy
2Laboratorio di Bioterapia, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, 16132 Genova, Italy
3Laboratorio di Patologica Clinica IRCCS Istituto Giannina Gaslini, 16148 Genova, Italy
4U.O. Oncologia IRCCS Istituto Giannina Gaslini, 16148 Genova, Italy

Received 1 August 2014; Accepted 25 September 2014

Academic Editor: Marco Antonio Velasco-Velázquez

Copyright © 2015 Fabio Morandi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Kroesen, D. Lindau, P. Hoogerbrugge, and G. J. Adema, “Immunocombination therapy for high-risk neuroblastoma.,” Immunotherapy, vol. 4, no. 2, pp. 163–174, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. M. Maris, “Recent advances in neuroblastoma,” The New England Journal of Medicine, vol. 362, no. 23, pp. 2154–2211, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. G. M. Brodeur, J. Pritchard, F. Berthold et al., “Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment,” Journal of Clinical Oncology, vol. 11, no. 8, pp. 1466–1477, 1993. View at Google Scholar · View at Scopus
  4. S. L. Cohn, A. D. J. Pearson, W. B. London et al., “The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 289–297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Shusterman, W. B. London, S. D. Gillies et al., “Antitumor activity of Hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study,” Journal of Clinical Oncology, vol. 28, no. 33, pp. 4969–4975, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Ladenstein, S. Weixler, B. Baykan et al., “Ch14.18 antibody produced in CHO cells in relapsed or refractory stage 4 neuroblastoma patients: a SIOPEN phase 1 study,” mAbs, vol. 5, no. 5, pp. 801–809, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. M. V. Corrias, M. Occhino, M. Croce et al., “Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression,” Tissue Antigens, vol. 57, no. 2, pp. 110–117, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Castriconi, A. Dondero, R. Augugliaro et al., “Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 34, pp. 12640–12645, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Castriconi, A. Dondero, F. Bellora et al., “Neuroblastoma-derived IL-β1 modulates the chemokine receptor repertoire of human resting nk cells,” Journal of Immunology, vol. 190, no. 10, pp. 5321–5328, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Morandi, G. Cangemi, S. Barco et al., “Plasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patients,” BioMed Research International, vol. 2013, Article ID 956878, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Morandi, P. Scaruffi, F. Gallo et al., “Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-g proteins,” PLoS ONE, vol. 7, no. 1, Article ID e29922, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Morandi, M. V. Corrias, I. Levreri et al., “Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients,” Cancer Immunology, Immunotherapy, vol. 60, no. 10, pp. 1485–1495, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Morandi, I. Levreri, P. Bocca et al., “Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release,” Cancer Research, vol. 67, no. 13, pp. 6433–6441, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. A. L. Yu, A. L. Gilman, M. F. Ozkaynak et al., “Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma,” New England Journal of Medicine, vol. 363, no. 14, pp. 1324–1334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. R. C. Seeger, “Immunology and immunotherapy of neuroblastoma,” Seminars in Cancer Biology, vol. 21, no. 4, pp. 229–237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Asgharzadeh, R. Pique-Regi, R. Sposto et al., “Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification,” Journal of the National Cancer Institute, vol. 98, no. 17, pp. 1193–1203, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Asgharzadeh, J. A. Salo, L. Ji et al., “Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma,” Journal of Clinical Oncology, vol. 30, no. 28, pp. 3525–3532, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Song, S. Asgharzadeh, J. Salo et al., “Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages,” Journal of Clinical Investigation, vol. 119, no. 6, pp. 1524–1536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Cao, “Regulatory T cells and immune tolerance to tumors,” Immunologic Research, vol. 46, no. 1–3, pp. 79–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Gowda, K. Godder, M. Kmieciak et al., “Distinct signatures of the immune responses in low risk versus high risk neuroblastoma,” Journal of Translational Medicine, vol. 9, article 170, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Groux, A. O'Garra, M. Bigler et al., “A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis,” Nature, vol. 389, no. 6652, pp. 737–742, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Battaglia, S. Gregori, R. Bacchetta, and M.-G. Roncarolo, “Tr1 cells: from discovery to their clinical application,” Seminars in Immunology, vol. 18, no. 2, pp. 120–127, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Gregori, K. S. Goudy, and M. G. Roncarolo, “The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells,” Frontiers in Immunology, vol. 3, article 30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. M. G. Roncarolo, S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings, “Interleukin-10-secreting type 1 regulatory T cells in rodents and humans,” Immunological Reviews, vol. 212, no. 1, pp. 28–50, 2006. View at Publisher · View at Google Scholar
  25. N. Gagliani, C. F. Magnani, S. Huber et al., “Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells,” Nature Medicine, vol. 19, no. 6, pp. 739–746, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Saraiva and A. O'Garra, “The regulation of IL-10 production by immune cells,” Nature Reviews Immunology, vol. 10, no. 3, pp. 170–181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Haupt, A. Garaventa, C. Gambini et al., “Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian neuroblastoma registry,” Journal of Clinical Oncology, vol. 28, no. 14, pp. 2331–2338, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Scaruffi, S. Stigliani, S. Moretti et al., “Transcribed-ultra conserved region expression is associated with outcome in high-risk neuroblastoma,” BMC Cancer, vol. 9, article 441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. V. F. Viprey, M. V. Corrias, B. Kagedal et al., “Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET,” European Journal of Cancer, vol. 43, no. 2, pp. 341–350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. T. L. Whiteside, “Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?” Cancer Immunology, Immunotherapy, vol. 63, no. 1, pp. 67–72, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Reinartz, T. Schumann, F. Finkernagel et al., “Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse,” International Journal of Cancer, vol. 134, no. 1, pp. 32–42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Wang, M. Sun, C. Gu et al., “Expression of CD163, interleukin-10, and interferon-gamma in oral squamous cell carcinoma: mutual relationships and prognostic implications,” European Journal of Oral Sciences, vol. 122, no. 3, pp. 202–209, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Prosniak, L. A. Harshyne, D. W. Andrews et al., “Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers,” Clinical Cancer Research, vol. 19, no. 14, pp. 3776–3786, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Fujio, T. Okamura, and K. Yamamoto, “The family of IL-10-secreting CD4+ T cells,” Advances in Immunology, vol. 105, pp. 99–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Tilak, S. Sherawat, S. Agarwala, R. Gupta, S. Vishnubhatla, and S. Bakhshi, “Circulating T-regulatory cells in neuroblastoma: a pilot prospective study,” Pediatric Hematology-Oncology, 2014. View at Publisher · View at Google Scholar
  37. V. Rigo, M. V. Corrias, A. M. Orengo et al., “Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity,” Cancer Immunology, Immunotherapy, vol. 63, no. 5, pp. 501–511, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Jing, X. Yan, W. H. D. Hallett, J. A. Gershan, and B. D. Johnson, “Depletion of CD25+ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma,” Blood, vol. 117, no. 25, pp. 6952–6962, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. W. Jing, J. A. Gershan, and B. D. Johnson, “Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory,” Blood, vol. 113, no. 18, pp. 4449–4457, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Croce, M. V. Corrias, A. M. Orengo et al., “Transient depletion of CD4+ T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice,” International Journal of Cancer, vol. 127, no. 5, pp. 1141–1150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Bergmann, L. Strauss, R. Zeidler, S. Lang, and T. L. Whiteside, “Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma,” Cancer Research, vol. 67, no. 18, pp. 8865–8873, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Bergmann, L. Strauss, Y. Wang et al., “T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease,” Clinical Cancer Research, vol. 14, no. 12, pp. 3706–3715, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Brignole, D. Marimpietri, F. Pastorino et al., “Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides,” Journal of Controlled Release, vol. 138, no. 2, pp. 122–127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. R. J. deLeeuw, S. E. Kost, J. A. Kakal, and B. H. Nelson, “The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature,” Clinical Cancer Research, vol. 18, no. 11, pp. 3022–3029, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Martin, S. Ladoire, G. Mignot, L. Apetoh, and F. Ghiringhelli, “Human FOXP3 and cancer,” Oncogene, vol. 29, no. 29, pp. 4121–4129, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Mussai, C. de Santo, I. Abu-Dayyeh et al., “Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment,” Blood, vol. 122, no. 5, pp. 749–758, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. P. C. Rodriguez, M. S. Ernstoff, C. Hernandez et al., “Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes,” Cancer Research, vol. 69, no. 4, pp. 1553–1560, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Rotondo, G. Barisione, L. Mastracci et al., “IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer,” International Journal of Cancer, vol. 125, no. 4, pp. 887–893, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. P. C. Rodriguez, D. G. Quiceno, J. Zabaleta et al., “Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses,” Cancer Research, vol. 64, no. 16, pp. 5839–5849, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Bronte and P. Zanovello, “Regulation of immune responses by L-arginine metabolism,” Nature Reviews Immunology, vol. 5, no. 8, pp. 641–654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. C. de Santo, P. Serafini, I. Marigo et al., “Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 11, pp. 4185–4190, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. P. N.-M. Cheng, T.-L. Lam, W.-M. Lam et al., “Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion,” Cancer Research, vol. 67, no. 1, pp. 309–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. E. S. Glazer, E. M. Stone, C. Zhu, K. L. Massey, A. N. Hamir, and S. A. Curley, “Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts,” Translational Oncology, vol. 4, no. 3, pp. 138–146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. M. T. Kuo, N. Savaraj, and L. G. Feun, “Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.,” Oncotarget, vol. 1, no. 4, pp. 246–251, 2010. View at Google Scholar · View at Scopus